Obstacles to getting more people with TB treated extend beyond cost. It starts with locating people at greatest risk and expanding preventive treatment programmes.
The push to end TB requires significant investment into the research and development of new diagnostics and treatments.
In Southern Africa, high rates of HIV infection have been the primary driver of TB
Treatment for drug-resistant TB remains problematic as the painful daily injectable patients receive for at least six months leaves more than 60% deaf.
Antibiotics that were not originally earmarked to treat TB have shown the first signs of effectiveness and could be added to the much-needed arsenal of drugs to fight the deadly disease.
In a bid to improve health care in South Africa, President Jacob Zuma has made several promises in the last three years. Some have materialised faster than others.
The closure of several mines in South Africa and production cuts could have a detrimental impact on the health of miners who rely on in-house HIV and TB treatment programmes.